Search

News

[Translate to English:]

Scientists from the Helmholtz Institute for RNA-based Infection Research (HIRI) and the Julius Maximilian University (JMU) in Würzburg have paved the way for a new diagnostic platform that enables the detection of multiple markers in one single test.

[Translate to English:]

Join Europe's Knowledge Transfer community at the sector's premier annual event uniting experts, professionals, and industry from around the world. The new office ticket allows you to participate with the whole team for just 1,500 EUR.

[Translate to English:]

BioVaria Startup Awards go to iRASP Therapeutics and OrganoTherapeutics

The current COVID-19 pandemic has drastically made us aware of how inadequate the present precautions are against infections transmitted by droplets…

Technology sneak peek from Ascenion: Seven breakthrough life-science inventions

[Translate to English:]

Heidelberg Pharma AG is allowed to initiate a Phase I/IIa clinical study in the US to evaluate the dosing, safety and anti-tumour efficacy of its lead candidate HDP-101 in multiple myeloma.

[Translate to English:]

16 partners from academia and industry will closely collaborate to prepare a future generation of scientists with outstanding skills in both machine learning and chemistry, to create new AI methods for drug research.

[Translate to English:]

Ascenion, technology transfer partner of Hannover Medical School (MHH), has supported the conclusion of a collaboration and licence agreement between MHH and Novo Nordisk.

This year’s BioVaria is digital and takes place exclusively online from the 26 to 28 April 2021.

[Translate to English:]

As part of its ‘GO-Bio initial’ programme, the BMBF has awarded Ascenion funding for its 'Life Science Digital Hub' concept to improve support for GO-Bio initial applicants.

[Translate to English:]

Merry Christmas!

We would like to thank all our clients, colleagues and partners in technology transfer, research and industry for the enjoyable and productive…

[Translate to English:]

Ascenion’s portfolio company HepaRegeniX achieves an important preclinical milestone indicating beneficial therapeutic effects of its lead candidate in certain liver carcinomas.

[Translate to English:]

An innovative approach to combat infections caused by Staphylococcus aureus will receive funding of initially 1.33 million USD plus an additional 7.44 million USD, depending on project progress. It is jointly developed by the HZI and the LDC.

[Translate to English:]

Ascenion’s portfolio company Cardior Pharmaceuticals announced positive results of a Phase Ib study with its first-in-class compound CDR132L.

[Translate to English:]

Ascenion will support eight members and four partners of the Innovative Training Network (ITN) ‘SMABEYOND’ in all aspects relating to the intellectual property and potential commercialization of their work.

Events